gptkbp:instanceOf
|
gptkb:public_company
|
gptkbp:CEO
|
gptkb:Marianne_De_Backer
|
gptkbp:collaboratesWith
|
gptkb:Alnylam_Pharmaceuticals
gptkb:Biogen
gptkb:Bill_&_Melinda_Gates_Foundation
GlaxoSmithKline
|
gptkbp:country
|
gptkb:United_States
|
gptkbp:currency
|
gptkb:USD
|
gptkbp:developedBy
|
vaccines
monoclonal antibodies
antiviral therapies
|
gptkbp:focusesOn
|
gptkb:COVID-19
gptkb:HIV
gptkb:hepatitis_B
immunology
infectious diseases
influenza
|
gptkbp:foundedYear
|
2016
|
gptkbp:hasCompany
|
gptkb:Vir_Biotechnology,_Inc.
|
gptkbp:headquartersLocation
|
gptkb:San_Francisco,_California,_United_States
|
https://www.w3.org/2000/01/rdf-schema#label
|
NASDAQ:VIR
|
gptkbp:industry
|
gptkb:biotechnology
|
gptkbp:ISIN
|
US92764N1028
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
gptkbp:market
|
biopharmaceuticals
|
gptkbp:notableProduct
|
gptkb:sotrovimab
|
gptkbp:numberOfEmployees
|
~400
|
gptkbp:product
|
gptkb:sotrovimab
|
gptkbp:stockSymbol
|
gptkb:NASDAQ
VIR
|
gptkbp:website
|
https://www.vir.bio/
|
gptkbp:bfsParent
|
gptkb:Vir_Biotechnology
|
gptkbp:bfsLayer
|
6
|